Deakin University
Browse

EpCAM immunotherapy versus specific targeted delivery of drugs

Download (1.78 MB)
Version 3 2024-06-18, 06:35
Version 2 2024-06-04, 11:48
Version 1 2018-07-09, 11:23
journal contribution
posted on 2024-06-18, 06:35 authored by Joanna MacdonaldJoanna Macdonald, J Henri, K Roy, E Hays, Michelle BauerMichelle Bauer, RN Veedu, N Pouliot, Sarah ShigdarSarah Shigdar
The epithelial cell adhesion molecule (EpCAM), or CD326, was one of the first cancer associated biomarkers to be discovered. In the last forty years, this biomarker has been investigated for use in personalized cancer therapy, with the first monoclonal antibody, edrecolomab, being trialled in humans more than thirty years ago. Since then, several other monoclonal antibodies have been raised to EpCAM and tested in clinical trials. However, while monoclonal antibody therapy has been investigated against EpCAM for almost 40 years as primary or adjuvant therapy, it has not shown as much promise as initially heralded. In this review, we look at the reasons why and consider alternative targeting options, such as aptamers, to turn this almost ubiquitously expressed epithelial cancer biomarker into a viable target for future personalized therapy.

History

Journal

Cancers

Volume

10

Article number

ARTN 19

Pagination

1 - 13

Location

Switzerland

Open access

  • Yes

ISSN

2072-6694

eISSN

2072-6694

Language

English

Publication classification

C1 Refereed article in a scholarly journal

Copyright notice

2018, The Authors

Issue

1

Publisher

MDPI